CEO Vikram Karnani was paid $1,715,846 in fiscal year 2025, ↓ down 84.1% from fiscal year 2024, the 1st percentile of its disclosed peer group (SEC filing 0001628280-26-024063 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$3,870,092 David Dieter total, FY2025 Executive Vice President and General Counsel — highest-paid officer; CEO Vikram Karnani: $1,715,846 | 1st CEO (Vikram Karnani) pay percentile vs peers | 8:1 CEO-to-median pay ratio | 95.98% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
COLL's next annual pay disclosure, estimated April 17, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| David Dieter | $384,615 | $0 | $3,189,732 | $0 | $277,183 | $0 | $18,562 | $3,870,092 |
| Executive Vice President and General Counsel | ||||||||
| Colleen Tupper | 559,340 | 0 | 2,484,486 | 0 | 449,289 | 0 | 21,940 | 3,515,055 |
| Executive Vice President and Chief Financial Officer | ||||||||
| Scott Dreyer | 523,236 | 0 | 2,160,473 | 0 | 335,563 | 0 | 21,940 | 3,041,212 |
| Executive Vice President and Chief Commercial Officer | ||||||||
| Shirley Kuhlmann | 115,522 | 0 | 1,966,013 | 0 | 0 | 0 | 702,048 | 2,783,583 |
| Former Executive Vice President, Chief Administrative Officer, General Counsel and Secretary | ||||||||
| Thomas Smith | 492,959 | 0 | 1,620,314 | 0 | 315,195 | 0 | 17,540 | 2,446,008 |
| Executive Vice President and Chief Medical Officer | ||||||||
| Vikram Karnani | 875,000 | 0 | 0 | 0 | 835,406 | 0 | 5,440 | 1,715,846 |
| President and Chief Executive Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| David Dieter | $3,870,092 | — | — | — |
| Colleen Tupper | 3,515,055 | 3,189,972 | 2,734,857 | ↑ +325,083 |
| Scott Dreyer | 3,041,212 | 2,791,375 | 2,612,380 | ↑ +249,837 |
| Shirley Kuhlmann | 2,783,583 | 3,301,296 | 2,874,147 | ↓ −517,713 |
| Thomas Smith | 2,446,008 | 2,500,083 | 2,044,802 | ↓ −54,075 |
| Vikram Karnani | 1,715,846 | 10,780,125 | — | ↓ −9,064,279 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Collegium Pharmaceutical's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper COLL reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses COLL in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named COLL in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Carlos Paya | Independent Director | $609,137 |
| Garen Bohlin | Independent Director | $366,639 |
| Gino Santini | Chair of the Board | $400,963 |
| Gwen Melincoff | Former director (through FY2025) | $20,549 |
| John Fallon | Independent Director | $366,268 |
| John Freund | Independent Director | $367,268 |
| Michael Donovan | Independent Director | — |
| Michael Heffernan | Former director (through FY2025) | $188,205 |
| Nancy Lurker | Independent Director | $743,776 |
| Rita Balice-Gordon | Independent Director | $342,268 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Garen Bohlin | Director | 2026-05-11 | D | 8,700 | $37 | $323,491 | Common | Form 4 ↗ |
| Garen Bohlin | Director | 2026-05-11 | A | 8,700 | 16 | 143,463 | Common | Form 4 ↗ |
| Garen Bohlin | Director | 2026-05-11 | D | 8,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nancy Lurker | Director | 2026-05-13 | D | 4,500 | 36 | 161,861 | Common | Form 4 ↗ |
| Gino Santini | Director | 2026-05-14 | A | 8,741 | 0 | 0 | Common | Form 4 ↗ |
| Carlos Paya | Director | 2026-05-14 | A | 8,741 | 0 | 0 | Common | Form 4 ↗ |
| Rita Balice-Gordon | Director | 2026-05-14 | A | 8,741 | 0 | 0 | Common | Form 4 ↗ |
| Donovan Michael Glancy | Director | 2026-05-14 | A | 17,482 | 0 | 0 | Common | Form 4 ↗ |
| Nancy Lurker | Director | 2026-05-14 | A | 8,741 | 0 | 0 | Common | Form 4 ↗ |
| John Freund | Director | 2026-05-14 | A | 8,741 | 0 | 0 | Common | Form 4 ↗ |
| Garen Bohlin | Director | 2026-05-14 | A | 8,741 | 0 | 0 | Common | Form 4 ↗ |
| John Freund | Director | 2026-05-15 | D | 8,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Freund | Director | 2026-05-15 | A | 8,700 | 16 | 143,463 | Common | Form 4 ↗ |
| John Freund | Director | 2026-05-15 | D | 4,127 | 35 | 142,547 | Common | Form 4 ↗ |
| John Freund | Director | 2026-05-18 | D | 20 | 34 | 681 | Common | Form 4 ↗ |
| Gino Santini | Director | 2026-06-08 | A | 8,700 | 16 | 143,463 | Common | Form 4 ↗ |
| Gino Santini | Director | 2026-06-08 | D | 8,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Scott Dreyer | PSU | 2025-02-10 | 1,929 | 3,858 | — | 7,716 | $150,308 |
| Colleen Tupper | PSU | 2025-02-10 | 2,219 | 4,437 | — | 8,874 | 170,869 |
| Shirley Kuhlmann | PSU | 2025-02-10 | 1,756 | 3,511 | — | 7,022 | 136,789 |
| David Dieter | PSU | 2025-03-17 | 2,934 | 5,867 | — | 11,734 | 220,893 |
| Colleen Tupper | PSU | 2025-02-10 | 4,438 | 8,875 | — | 17,750 | 389,435 |
| Thomas Smith | PSU | 2025-02-10 | 2,894 | 5,787 | — | 11,574 | 253,934 |
| Shirley Kuhlmann | PSU | 2025-02-10 | 3,512 | 7,023 | — | 14,046 | 308,169 |
| Thomas Smith | PSU | 2025-02-10 | 1,447 | 2,894 | — | 5,788 | 112,750 |
| David Dieter | PSU | 2025-03-17 | 2,934 | 5,867 | — | 11,734 | 220,541 |
| Thomas Smith | PSU | 2025-02-10 | 1,447 | 2,894 | — | 5,788 | 111,448 |
| Colleen Tupper | PSU | 2025-02-10 | 2,219 | 4,437 | — | 8,874 | 171,357 |
| Colleen Tupper | PSU | 2025-02-10 | 2,219 | 4,437 | — | 8,874 | 172,866 |
| Thomas Smith | PSU | 2025-02-10 | 1,447 | 2,894 | — | 5,788 | 111,766 |
| Shirley Kuhlmann | PSU | 2025-02-10 | 1,756 | 3,511 | — | 7,022 | 135,209 |
| David Dieter | PSU | 2025-03-17 | 2,934 | 5,867 | — | 11,734 | 218,956 |
| Shirley Kuhlmann | RSU | 2025-02-10 | — | — | 40,965 | — | 1,250,252 |
| Thomas Smith | RSU | 2025-02-10 | — | — | 33,762 | — | 1,030,416 |
| Colleen Tupper | RSU | 2025-02-10 | — | — | 51,768 | — | 1,579,959 |
| Scott Dreyer | RSU | 2025-02-10 | — | — | 45,016 | — | 1,373,888 |
| Scott Dreyer | PSU | 2025-02-10 | 1,929 | 3,858 | — | 7,716 | 148,996 |
| Scott Dreyer | PSU | 2025-02-10 | 1,929 | 3,858 | — | 7,716 | 148,572 |
| Scott Dreyer | PSU | 2025-02-10 | 3,860 | 7,719 | — | 15,438 | 338,710 |
| David Dieter | RSU | 2025-03-17 | — | — | 68,449 | — | 2,030,882 |
| Shirley Kuhlmann | PSU | 2025-02-10 | 1,756 | 3,511 | — | 7,022 | 135,595 |
| David Dieter | PSU | 2025-03-17 | 5,867 | 11,734 | — | 23,468 | 498,460 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Scott Dreyer | $1,373,888 | $786,586 | $0 | 36.4% |
| Colleen Tupper | 1,579,959 | 904,527 | 0 | 36.4% |
| Shirley Kuhlmann | 1,250,252 | 715,762 | 0 | 36.4% |
| David Dieter | 2,030,882 | 1,158,850 | 0 | 36.3% |
| Thomas Smith | 1,030,416 | 589,898 | 0 | 36.4% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| David Dieter | PSU | 46,936 | — | $2,173,137 |
| Thomas Smith | RSU | 24,934 | — | 1,154,444 |
| Scott Dreyer | RSU | 28,334 | — | 1,311,864 |
| Scott Dreyer | RSU | 41,918 | — | 1,940,803 |
| Thomas Smith | RSU | 29,525 | — | 1,367,008 |
| David Dieter | RSU | 77,454 | — | 3,586,120 |
| Colleen Tupper | PSU | 20,880 | — | 966,744 |
| Scott Dreyer | RSU | 13,125 | — | 607,688 |
| Vikram Karnani | RSU | 112,010 | — | 5,186,063 |
| Colleen Tupper | RSU | 42,647 | — | 1,974,556 |
| Vikram Karnani | Option | 97,758 | 31.41 | — |
| Vikram Karnani | PSU | 169,556 | — | 7,850,443 |
| Colleen Tupper | RSU | 58,578 | — | 2,715,161 |
| Colleen Tupper | PSU | 35,498 | — | 1,643,557 |
| Colleen Tupper | RSU | 32,867 | — | 1,521,742 |
| Colleen Tupper | RSU | 13,125 | — | 607,688 |
| Scott Dreyer | RSU | 50,938 | — | 2,358,429 |
| Thomas Smith | RSU | 38,204 | — | 1,768,845 |
| Scott Dreyer | PSU | 30,870 | — | 1,429,281 |
| Thomas Smith | PSU | 23,150 | — | 1,071,845 |
| Scott Dreyer | PSU | 18,000 | — | 833,400 |
| Thomas Smith | PSU | 15,840 | — | 733,392 |
Our executive compensation programs are designed to reward the achievement of our short- and long-term strategic objectives and to drive the creation of long-term shareholder value by successfully executing our business strategy.
| CEO STI target (% of salary) | 75% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards, LLC |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-14 | 26,313,792 | 1,100,723 | 5,646 | 95.98% | Passed |
| 2025 | 2025-05-15 | 22,867,414 | 2,233,541 | 2,544,266 | 91.1% | Passed |
| 2024 | 2024-05-16 | 28,311,783 | 350,755 | 36,150 | 98.78% | Passed |
| 2023 | 2023-05-18 | 27,953,926 | 315,383 | 90,502 | 98.88% | Passed |
| 2022 | 2022-05-23 | 28,337,587 | 643,459 | 35,822 | 97.78% | Passed |
| 2021 | 2021-05-20 | 29,689,528 | 353,660 | 46,170 | 98.82% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-14 | 95.98%a |
| 2025 | 2025-05-15 | 91.1%b |
| 2024 | 2024-05-16 | 98.78%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast either " FOR " or " AGAINST " this proposal and, thus, will have no impact on the outcome of Executive Vice President, General Counsel and Corporate Secretary • Mr.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast either " FOR " or " AGAINST " this proposal and, thus, will have no impact on the outcome of eral Counsel since March 2025.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast either " FOR " or " AGAINST " this proposal and, thus, will have no impact on the outcome of erations;”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 8 : 1 |
|---|---|
| CEO total compensation | $1,715,846 |
| Median employee compensation | $221,391 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Nancy LurkerIndependent · Compliance (Chair) · Compensation | $62,893 | $680,883 | $0 | $0 | $0 | $743,776 |
| Carlos PayaIndependent · Transaction (Chair) · Nominating and Corporate Governance | 34,601 | 574,536 | 0 | 0 | 0 | 609,137 |
| Gino SantiniIndependent · Board Chair · Compensation · Transaction | 113,695 | 287,268 | 0 | 0 | 0 | 400,963 |
| John FreundIndependent · Compensation (Chair) · Audit | 80,000 | 287,268 | 0 | 0 | 0 | 367,268 |
| Garen BohlinIndependent · Audit (Chair) · Compliance | 79,371 | 287,268 | 0 | 0 | 0 | 366,639 |
| John FallonIndependent · Nominating and Corporate Governance (Chair) · Audit · Compliance · Not standing for re-election | 79,000 | 287,268 | 0 | 0 | 0 | 366,268 |
| Rita Balice-GordonIndependent · Nominating and Corporate Governance · Transaction | 55,000 | 287,268 | 0 | 0 | 0 | 342,268 |
| Michael HeffernanIndependent · Departed during FY | 41,099 | 147,106 | 0 | 0 | 0 | 188,205 |
| Gwen MelincoffIndependent · Departed during FY | 20,549 | — | 0 | 0 | 0 | 20,549 |
| Michael DonovanIndependent · Audit · Compliance · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Vikram KarnaniEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $275,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 20,000 / 10,000 |
| Stock ownership guideline | 3x annual cash retainer for non-employee directors |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $566,208 |
| Equity awards (grant-date value) | $2,838,865 |
| All other compensation | $0 |
| Total cost of the board | $3,405,073 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Collegium Pharmaceutical names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Collegium Pharmaceutical.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | BioCryst Pharmaceuticals, Inc. | 2025 | Jon Stonehouse | $728,466 | $0 | $11,132,458 | $1,052,633 | $12,951,082 |
| 2 | ANI Pharmaceuticals, Inc. | 2025 | Nikhil Lalwani | 837,409 | 7,848,711 | 0 | 1,572,500 | 10,278,620 |
| 3 | Amicus Therapeutics, Inc. | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 4 | Amphastar Pharmaceuticals, Inc. | 2025 | Jack Yongfeng Zhang | 950,911 | 3,301,981 | 3,302,024 | 361,000 | 8,309,350 |
| 5 | ACADIA Pharmaceuticals, Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 6 | Catalyst Pharmaceuticals, Inc. | 2024 | Richard Daly | 750,000 | 1,267,601 | 5,070,830 | 0 | 7,774,160 |
| 7 | Collegium Pharmaceutical | 2025 | Vikram Karnani | 875,000 | 0 | 0 | 835,406 | 1,715,846 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Collegium Pharmaceutical | 127.3% | RSU 70 · PSU 30 | Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry Index | Alpine Rewards, LLC |
| ACADIA Pharmaceuticals, Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Amicus Therapeutics, Inc. | not disclosed | Option 33 · RSU 33 · PRSU 33 | Yes — TSR Goal | Pay Governance |
| Amphastar Pharmaceuticals, Inc. | not disclosed | Options 50 · RSU 50 | not disclosed | Willis Towers Watson (WTW) |
| ANI Pharmaceuticals, Inc. | 185% | RSU 75 · PSU 25 | Yes — relative TSR against the constituents of the S&P 600 Pharmaceuticals, Biotechnology and Life Sciences Index | Pearl Meyer & Partners, LLC |
| BioCryst Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Catalyst Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | Mercer LLC |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, David Dieter | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Summary Compensation Table”. As printed: 3,870,092. Filing ↗machine: r8 · c48 · span 801432–801441 |
| 2 | Section 01, Colleen Tupper | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Summary Compensation Table”. As printed: 3,515,055. Filing ↗machine: r5 · c48 · span 790338–790347 |
| 3 | Section 01, Scott Dreyer | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Summary Compensation Table”. As printed: 3,041,212. Filing ↗machine: r11 · c48 · span 812129–812138 |
| 4 | Section 01, Shirley Kuhlmann | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Summary Compensation Table”. As printed: 2,783,583. Filing ↗machine: r17 · c48 · span 834020–834029 |
| 5 | Section 01, Thomas Smith | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Summary Compensation Table”. As printed: 2,446,008. Filing ↗machine: r14 · c48 · span 823230–823239 |
| 6 | Section 01, Vikram Karnani | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Summary Compensation Table”. As printed: 1,715,846. Filing ↗machine: r2 · c48 · span 779394–779403 |
| 7 | Section 03, Scott Dreyer PSU | DEF 14A | 1900-01-01 | 0001628280-26-024063 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 893172–893179 |
| 8 | Section 03, Colleen Tupper PSU | DEF 14A | 1900-01-01 | 0001628280-26-024063 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 866204–866211 |
| 9 | Section 03, Shirley Kuhlmann PSU | DEF 14A | 1900-01-01 | 0001628280-26-024063 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 922788–922795 |
| 10 | Section 03, David Dieter PSU | DEF 14A | 1900-01-01 | 0001628280-26-024063 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 883384–883391 |
| 11 | Section 03, Colleen Tupper PSU | DEF 14A | 1900-01-01 | 0001628280-26-024063 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 871131–871138 |
| 12 | Section 03, Thomas Smith PSU | DEF 14A | 1900-01-01 | 0001628280-26-024063 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 915279–915286 |
| 13 | Section 03, Shirley Kuhlmann PSU | DEF 14A | 1900-01-01 | 0001628280-26-024063 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 930178–930185 |
| 14 | Section 03, Thomas Smith PSU | DEF 14A | 1900-01-01 | 0001628280-26-024063 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 907889–907896 |
| 15 | Section 03, David Dieter PSU | DEF 14A | 1900-01-01 | 0001628280-26-024063 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 880919–880926 |
| 16 | Section 03, Thomas Smith PSU | DEF 14A | 1900-01-01 | 0001628280-26-024063 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 910352–910359 |
| 17 | Section 03, Colleen Tupper PSU | DEF 14A | 1900-01-01 | 0001628280-26-024063 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 868667–868674 |
| 18 | Section 03, Colleen Tupper PSU | DEF 14A | 1900-01-01 | 0001628280-26-024063 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 863741–863748 |
| 19 | Section 03, Thomas Smith PSU | DEF 14A | 1900-01-01 | 0001628280-26-024063 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 912815–912822 |
| 20 | Section 03, Shirley Kuhlmann PSU | DEF 14A | 1900-01-01 | 0001628280-26-024063 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 925251–925258 |
| 21 | Section 03, David Dieter PSU | DEF 14A | 1900-01-01 | 0001628280-26-024063 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 878454–878461 |
| 22 | Section 03, Shirley Kuhlmann RSU | DEF 14A | 1900-01-01 | 0001628280-26-024063 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 932312–932321 |
| 23 | Section 03, Thomas Smith RSU | DEF 14A | 1900-01-01 | 0001628280-26-024063 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 917413–917422 |
| 24 | Section 03, Colleen Tupper RSU | DEF 14A | 1900-01-01 | 0001628280-26-024063 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 873265–873274 |
| 25 | Section 03, Scott Dreyer RSU | DEF 14A | 1900-01-01 | 0001628280-26-024063 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 902696–902705 |
| 26 | Section 03, Scott Dreyer PSU | DEF 14A | 1900-01-01 | 0001628280-26-024063 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 898098–898105 |
| 27 | Section 03, Scott Dreyer PSU | DEF 14A | 1900-01-01 | 0001628280-26-024063 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 895635–895642 |
| 28 | Section 03, Scott Dreyer PSU | DEF 14A | 1900-01-01 | 0001628280-26-024063 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 900562–900569 |
| 29 | Section 03, David Dieter RSU | DEF 14A | 1900-01-01 | 0001628280-26-024063 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 887985–887994 |
| 30 | Section 03, Shirley Kuhlmann PSU | DEF 14A | 1900-01-01 | 0001628280-26-024063 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 927714–927721 |
| 31 | Section 03, David Dieter PSU | DEF 14A | 1900-01-01 | 0001628280-26-024063 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 885850–885857 |
| 32 | Section 07, pay ratio | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “CEO Pay Ratio”. As printed: 8 : 1. Filing ↗machine: span 1114023–1114024 |
| 33 | Section 08, Nancy Lurker | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Director Compensation”. As printed: 743,776. Filing ↗machine: t50 · r7 · c8 · span 487255–487558 |
| 34 | Section 08, Carlos Paya | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Director Compensation”. As printed: 609,137. Filing ↗machine: t50 · r9 · c8 · span 490574–490877 |
| 35 | Section 08, Gino Santini | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Director Compensation”. As printed: 400,963. Filing ↗machine: t50 · r10 · c8 · span 492040–492343 |
| 36 | Section 08, John Freund | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Director Compensation”. As printed: 367,268. Filing ↗machine: t50 · r5 · c8 · span 483938–484241 |
| 37 | Section 08, Garen Bohlin | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Director Compensation”. As printed: 366,639. Filing ↗machine: t50 · r3 · c8 · span 480998–481301 |
| 38 | Section 08, John Fallon | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Director Compensation”. As printed: 366,268. Filing ↗machine: t50 · r4 · c8 · span 482468–482771 |
| 39 | Section 08, Rita Balice-Gordon | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Director Compensation”. As printed: 342,268. Filing ↗machine: t50 · r2 · c8 · span 479471–479805 |
| 40 | Section 08, Michael Heffernan | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Director Compensation”. As printed: 188,205. Filing ↗machine: t50 · r6 · c8 · span 485602–485905 |
| 41 | Section 08, Gwen Melincoff | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Director Compensation”. As printed: 20,549. Filing ↗machine: t50 · r8 · c2 · span 488161–488399 |
| 42 | Section 08, Michael Donovan | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 43 | Section 08, Vikram Karnani | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 44 | Section 02, Garen Bohlin 2026-05-11 | Form 4 | 2026-05-13 | 0001254705-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Garen Bohlin 2026-05-11 | Form 4 | 2026-05-13 | 0001254705-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Garen Bohlin 2026-05-11 | Form 4 | 2026-05-13 | 0001254705-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Nancy Lurker 2026-05-13 | Form 4 | 2026-05-15 | 0001450485-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Gino Santini 2026-05-14 | Form 4 | 2026-05-18 | 0001276038-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Carlos Paya 2026-05-14 | Form 4 | 2026-05-18 | 0001606244-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Rita Balice-Gordon 2026-05-14 | Form 4 | 2026-05-18 | 0001825625-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Donovan Michael Glancy 2026-05-14 | Form 4 | 2026-05-18 | 0002134015-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Nancy Lurker 2026-05-14 | Form 4 | 2026-05-18 | 0001450485-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, John Freund 2026-05-14 | Form 4 | 2026-05-18 | 0001296771-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Garen Bohlin 2026-05-14 | Form 4 | 2026-05-18 | 0001254705-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, John Freund 2026-05-15 | Form 4 | 2026-05-18 | 0001296771-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, John Freund 2026-05-15 | Form 4 | 2026-05-18 | 0001296771-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, John Freund 2026-05-15 | Form 4 | 2026-05-18 | 0001296771-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, John Freund 2026-05-18 | Form 4 | 2026-05-20 | 0001296771-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Gino Santini 2026-06-08 | Form 4 | 2026-06-10 | 0001276038-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Gino Santini 2026-06-08 | Form 4 | 2026-06-10 | 0001276038-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 06, 2026 vote | Form 8-K | 2026-05-15 | 0001104659-26-062536 | Item 5.07 · say-on-pay result. As reported: 95.98% (votes for as printed: 26,313,792). Filing ↗ |
| 62 | Section 06, 2025 vote | Form 8-K | 2025-05-19 | 0001104659-25-050435 | Item 5.07 · say-on-pay result. As reported: 91.1% (votes for as printed: 22,867,414). Filing ↗ |
| 63 | Section 06, 2024 vote | Form 8-K | 2024-05-20 | 0001104659-24-063396 | Item 5.07 · say-on-pay result. As reported: 98.78% (votes for as printed: 28,311,783). Filing ↗ |
| 64 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 65 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 66 | Section 09b board cost (computed) | Computed | — | — | Cash 566,208 + equity 2,838,865 + all other 0 = 3,405,073, summed across the director compensation table rows.machine: formula: Σ = 3,405,073 |
| 67 | BioCryst Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001628280-26-026822 | CEO total compensation as printed in BioCryst Pharmaceuticals, Inc.'s own proxy. As printed: 12,951,082. Filing ↗machine: span 512256–512266 |
| 68 | ANI Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-09 | 0001023024-26-000039 | CEO total compensation as printed in ANI Pharmaceuticals, Inc.'s own proxy. As printed: 10,278,620. Filing ↗machine: r2 · c48 · span 484144–484154 |
| 69 | Amicus Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-24 | 0001140361-25-015479 | CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736126–736136 |
| 70 | Amphastar Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-13 | 0001297184-26-000023 | CEO total compensation as printed in Amphastar Pharmaceuticals, Inc.'s own proxy. As printed: 8,309,350. Filing ↗machine: span 722923–722932 |
| 71 | ACADIA Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-174163 | CEO total compensation as printed in ACADIA Pharmaceuticals, Inc.'s own proxy. As printed: 8,256,518. Filing ↗ |
| 72 | Catalyst Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2025-04-11 | 0001193125-25-079097 | CEO total compensation as printed in Catalyst Pharmaceuticals, Inc.'s own proxy. As printed: 7,774,160. Filing ↗ |
| 73 | Collegium Pharmaceutical (subject), Section 10b CEO total | DEF 14A | 2026-04-07 | 0001628280-26-024063 | CEO total compensation as printed in Collegium Pharmaceutical's own proxy. As printed: 1,715,846. Filing ↗machine: r2 · c48 · span 779394–779403 |
| 74 | Section 10a, ANI Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001023024-26-000039 | ANI Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Collegium Pharmaceutical. Filing ↗ |
| 75 | Section 10a, BioCryst Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001628280-26-026822 | BioCryst Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Collegium Pharmaceutical. Filing ↗ |
| 76 | Section 10a, ACADIA Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001193125-26-174163 | ACADIA Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Collegium Pharmaceutical. Filing ↗ |
| 77 | Section 10a, Catalyst Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001193125-25-079097 | Catalyst Pharmaceuticals, Inc. names Collegium Pharmaceutical in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 78 | Section 10a, Amicus Therapeutics, Inc. reciprocity | DEF 14A | — | 0001140361-25-015479 | Amicus Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Collegium Pharmaceutical. Filing ↗ |
| 79 | Section 10a, Amphastar Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001297184-26-000023 | Amphastar Pharmaceuticals, Inc. names Collegium Pharmaceutical in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.